## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 82%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($305.31)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 68% Above Its Share Price**
- Source: Yahoo Finance | 20251207T120937 | Bullish | Relevance: 99%
-  According to Simply Wall St's analysis, Amgen Inc. (NASDAQ:AMGN) appears significantly undervalued with an estimated intrinsic value of US$554, which is 68% above its current share price of US$330. The analysis uses a 2-stage Discounted Cash Flow (DCF) model and suggests a potential 40% undervaluation. However, it's noted that the analyst price target for AMGN is US$324, indicating a discrepancy with Simply Wall St's fair value estimate.

**2. Has the Market Fully Priced In Amgenâ€™s Rally After Pipeline and Regulatory Milestones?**
- Source: Simply Wall Street | 20251207T030903 | Somewhat-Bullish | Relevance: 99%
-  Amgen's stock has seen significant gains, up 27.2% year to date, fueled by an expanding pipeline and regulatory milestones. Analysis using Discounted Cash Flow and Price vs. Earnings models suggests Amgen is currently undervalued. The article presents bullish and bearish narratives for Amgen, with fair value estimates ranging from $322.88 to $404.87 per share.

**3. Amgen (NASDAQ:AMGN) Cut to "Buy" at Wall Street Zen**
- Source: MarketBeat | 20251207T060753 | Somewhat-Bullish | Relevance: 99%
-  Wall Street Zen downgraded Amgen (NASDAQ:AMGN) from a "strong-buy" to a "buy" rating, though the stock retains a "Moderate Buy" consensus rating with an average target price of $335.65. Despite beating earnings expectations with $5.64 EPS and $9.56 billion revenue, the stock opened down 3%. Recent insider selling totaled 10,908 shares worth approximately $3.67 million, while institutional investors and hedge funds hold about 76.5% of the company.

**4. Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc.**
- Source: MarketBeat | 20251209T103052 | Somewhat-Bullish | Relevance: 99%
-  Daiwa Securities Group Inc. has increased its holdings in Amgen Inc. by 5.1% in the second quarter, bringing its total ownership to 229,666 shares valued at $64.125 million. Several other hedge funds also adjusted their stakes in Amgen, while some corporate insiders sold shares. Wall Street analysts have issued mixed ratings for Amgen, with a consensus "Moderate Buy" and an average target price of $335.65.

**5. Bank of Nova Scotia Has $29.83 Million Stake in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251209T085453 | Bullish | Relevance: 99%
- Bank of Nova Scotia increased its stake in Amgen Inc. to 106,815 shares valued at $29.83 million during the second quarter, representing a 29.1% increase. Other institutional investors, including Norges Bank, also significantly boosted their holdings, with overall institutional ownership now at 76.5%. Amgen reported strong Q2 earnings, beating analyst estimates for both EPS and revenue, and announced a quarterly dividend of $2.38 per share.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 14.7x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $173.0B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 14.7 |
| Current P/E | 15.1 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.1% to -6.7% (-6.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 10.7pp (needs >4.0% for momentum thesis). AM_20 at -4.7% indicates price below own 20MA trend. Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-3.13), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -6.65% (CS: 6) | Weak |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | -3.13 | Bearish |
| vs SMA20 | 0.952x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.082x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $321.23
- **Stop Loss:** $305.31 (5.0% risk)
- **Target:** $353.07 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $9,958.13
- **Portfolio %:** 9.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*